Wegovy for Type 2 Diabetes: Is It Prescribed for This Condition?

Is Wegovy actually licensed to treat type 2 diabetes?

No. In the UK, Wegovy is licensed by the MHRA for weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. Type 2 diabetes is one of the conditions that can satisfy that second threshold, but the medicine is being used to address weight, not to treat the diabetes itself. It's a distinction that the NHS semaglutide guidance draws clearly.

The confusion is understandable. Ozempic is the same active ingredient (semaglutide) but at doses of 0.5mg and 1mg, licensed specifically for blood-sugar control in type 2 diabetes. Wegovy runs to 2.4mg maintenance dosing and is approved for a different clinical purpose. If you've heard of people with diabetes using semaglutide and felt unsure which product was meant, that's why. Our page on semaglutide and type 2 diabetes unpacks the distinction between these products in more detail.

A question our prescribers hear most weeks is some version of: "I have type 2 diabetes, can I still get Wegovy for my weight?" The short answer is: possibly, but only after a thorough clinical review, and our page on whether Wegovy is used for type 2 diabetes walks through exactly what that means in practice. Your diabetes medications, your current HbA1c, how stable your condition is, and whether your GP is involved all factor into that decision.

What does the evidence say about semaglutide, weight, and blood-sugar control?

The STEP 1 trial, published in the New England Journal of Medicine, showed that semaglutide 2.4mg produced an average body-weight reduction of around 15% over 68 weeks, a figure that carries real significance for people whose weight is complicating their diabetes management. Sustained weight loss at that scale can improve insulin sensitivity, lower HbA1c, and in some cases allow a reduction in diabetes medication under medical supervision.

That doesn't mean Wegovy treats type 2 diabetes. What it means is that for someone whose primary clinical goal is weight reduction (and who happens to have type 2 diabetes) the overlap between the two is clinically important to manage carefully. Your prescriber needs to know about every diabetes medication you take, because adjustments may be needed as your weight and blood-sugar levels change. This is not something to navigate alone. For a broader look at how semaglutide and diabetes intersect, the wegovy and diabetes overview covers the landscape in fuller detail.

What are the specific considerations if you have type 2 diabetes and want to start Wegovy?

Several factors become more pressing when type 2 diabetes is part of the picture. First, hypoglycaemia risk: GLP-1 receptor agonists rarely cause low blood sugar on their own, but if you're also taking insulin or a sulphonylurea, the combination can. Your prescriber may want to reduce those doses before or shortly after starting Wegovy, never do this without guidance.

Second, kidney function. Severe dehydration from GLP-1-related nausea or vomiting can strain the kidneys, which matters more if yours are already under pressure from long-standing diabetes. Third, gastroparesis (delayed stomach emptying) is more common in people with diabetes and can worsen on GLP-1 therapy, it's a contraindication worth discussing.

Wegovy is not recommended during pregnancy, if you're breastfeeding, or if you're trying to conceive. Under-18s are not within the licensed population. People with a history of medullary thyroid carcinoma or MEN2 should not take it. The MHRA has also highlighted acute pancreatitis as a known but infrequent serious risk, seek urgent help for severe stomach pain that radiates to the back. You can report any suspected side effects through the MHRA's Yellow Card scheme.

If you have type 2 diabetes and are exploring weight management options, the most productive first step is a clinical consultation, and our dedicated page on Wegovy and type 1 diabetes is also worth reading if you or someone close to you is living with the type 1 condition. At nume, every enquiry is reviewed personally by a GPhC-registered Independent Prescriber, your diabetes medications and health history are part of that review, not an afterthought. You can start your free consultation here.

Does having type 2 diabetes change how Wegovy fits within NHS access or private treatment?

On the NHS, Wegovy is commissioned through specialist weight management services under NICE appraisal TA875, which requires a BMI of 35 or above alongside at least one weight-related comorbidity (type 2 diabetes qualifies as one) within a multidisciplinary service, for a maximum of two years. Waiting lists for those services are long in many areas, and NHS access criteria remain strict.

Privately, the licensed eligibility thresholds are set by the Wegovy SmPC: BMI 30 or above, or 27 or above with a qualifying condition. Type 2 diabetes is one of those conditions. That means many people with type 2 diabetes do meet the private eligibility criteria for weight management treatment, but meeting a BMI threshold is only one part of the assessment. For context on what private treatment typically costs, our Wegovy cost guide sets out how pricing works without the guesswork. The wider Wegovy treatment overview is a good starting point if you're still building a picture of what the medicine involves.